From 100012.1163@CompuServe.COM Sat Dec 18 12:57:15 1993 Received: from dub-img-1.compuserve.com for 100012.1163@CompuServe.COM by www.ccl.net (8.6.4/930601.1506) id MAA03375; Sat, 18 Dec 1993 12:24:12 -0500 Received: from localhost by dub-img-1.compuserve.com (8.6.4/5.930129sam) id MAA13833; Sat, 18 Dec 1993 12:23:34 -0500 Date: 18 Dec 93 12:19:25 EST From: "100012.1163@compuserve.com Rainer Stumpe" <100012.1163@CompuServe.COM> To: Subject: Re: De Novo Drug design Message-ID: <931218171925_100012.1163_BHB53-1@CompuServe.COM> To: >internet:CHEMISTRY@ccl.net Dear Fellow Netters, About two or three years ago, Hoffmann-La Roche of Switzerland brought the first "designed" drug to the market. It is a drug that passes the blood/brain barrier, and is converted by an ezymatic reaction in the brain to the active compound. The pre- drug was modelled for that enzyme. As far as I know, the German chemical and pharmaceutical industries use Molecular Modelling extensively. following their demand, there have been several new position for computational chemistry professors founded during the past five years to teach students the basics of modelling. Our MM software MOBY is equally successful in industry and universities. With the compliments of the season, Dr. Rainer Stumpe Springer-Verlag Chemistry Editorial Tiergartenstr. 17 D-69121 Heidelberg INTERNET:STUMPE@SPINT.COMPUSERVE.COM